ID   KPUM-MS3
AC   CVCL_A1JT
SY   MS-3; Kyoto Prefectural University of Medicine-MS3
DR   Wikidata; Q102114433
RX   PubMed=21640157;
CC   Population: Japanese.
CC   Sequence variation: Gene fusion; HGNC; HGNC:990; BCL2 + HGNC; HGNC:5477; IGH; Name(s)=IGH-BCL2 (PubMed=21640157).
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C8851; Diffuse large B-cell lymphoma
DI   ORDO; Orphanet_544; Diffuse large B-cell lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   67Y
CA   Cancer cell line
DT   Created: 29-10-20; Last updated: 19-12-24; Version: 6
//
RX   PubMed=21640157; DOI=10.1016/j.exphem.2011.05.002;
RA   Sasaki N., Kuroda J., Nagoshi H., Yamamoto M., Kobayashi S.,
RA   Tsutsumi Y., Kobayashi T., Shimura Y., Matsumoto Y., Taki T.,
RA   Nishida K., Horiike S., Akao Y., Taniwaki M.;
RT   "Bcl-2 is a better therapeutic target than c-Myc, but attacking both
RT   could be a more effective treatment strategy for B-cell lymphoma with
RT   concurrent Bcl-2 and c-Myc overexpression.";
RL   Exp. Hematol. 39:817-828.e1(2011).
//